An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...

GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.

VIDA Partners with Riverain Technologies to Extend Best-of-Breed AI Imaging for Life Sciences Riverain's cardiothoracic AI suite is now available to sponsors with VIDA's clinical trial imaging ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...

SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains ...

Generate:Biomedicines to begin global phase 3 studies of GB-0895, a long-acting anti-TSLP antibody for severe asthma engineered with AI: Somerville, Massachusetts Tuesday, Decembe ...

Company to host video conference call and webcast at 8:00 a.m. ET on Monday, December 8, 2025WATERTOWN, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) ...

West Virginia wasn’t the only state with anti-tobacco initiatives that suffered after OSH closed down. New York state’s ...

Biomoneta Research Private Limited, a Bengaluru-based healthtech company, announces it has received US Food and Drug ...

Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.

ReAlta Life Sciences, Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute ...